These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 37106795)

  • 1. From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria.
    Amorim R; Magalhães CC; Borges F; Oliveira PJ; Teixeira J
    Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease.
    Grattagliano I; Montezinho LP; Oliveira PJ; Frühbeck G; Gómez-Ambrosi J; Montecucco F; Carbone F; Wieckowski MR; Wang DQ; Portincasa P
    Biochem Pharmacol; 2019 Feb; 160():34-45. PubMed ID: 30508523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte Mitochondrial Dynamics and Bioenergetics in Obesity-Related Non-Alcoholic Fatty Liver Disease.
    Legaki AI; Moustakas II; Sikorska M; Papadopoulos G; Velliou RI; Chatzigeorgiou A
    Curr Obes Rep; 2022 Sep; 11(3):126-143. PubMed ID: 35501558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
    Geng Y; Faber KN; de Meijer VE; Blokzijl H; Moshage H
    Hepatol Int; 2021 Feb; 15(1):21-35. PubMed ID: 33548031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
    Rada P; González-Rodríguez Á; García-Monzón C; Valverde ÁM
    Cell Death Dis; 2020 Sep; 11(9):802. PubMed ID: 32978374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
    Ramanathan R; Ali AH; Ibdah JA
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.
    Di Ciaula A; Calamita G; Shanmugam H; Khalil M; Bonfrate L; Wang DQ; Baffy G; Portincasa P
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease.
    Arguello G; Balboa E; Arrese M; Zanlungo S
    Biochim Biophys Acta; 2015 Sep; 1852(9):1765-78. PubMed ID: 26027904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
    Di Ciaula A; Passarella S; Shanmugam H; Noviello M; Bonfrate L; Wang DQ; Portincasa P
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Alterations of Mitochondrial Function during NAFLD Progression-An Independent Effect of Mitochondrial ROS Production.
    Simões ICM; Amorim R; Teixeira J; Karkucinska-Wieckowska A; Carvalho A; Pereira SP; Simões RF; Szymanska S; Dąbrowski M; Janikiewicz J; Dobrzyń A; Oliveira PJ; Potes Y; Wieckowski MR
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship.
    Karkucinska-Wieckowska A; Simoes ICM; Kalinowski P; Lebiedzinska-Arciszewska M; Zieniewicz K; Milkiewicz P; Górska-Ponikowska M; Pinton P; Malik AN; Krawczyk M; Oliveira PJ; Wieckowski MR
    Eur J Clin Invest; 2022 Mar; 52(3):e13622. PubMed ID: 34050922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression.
    Bellanti F; Villani R; Tamborra R; Blonda M; Iannelli G; di Bello G; Facciorusso A; Poli G; Iuliano L; Avolio C; Vendemiale G; Serviddio G
    Redox Biol; 2018 May; 15():86-96. PubMed ID: 29220698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
    Rives C; Fougerat A; Ellero-Simatos S; Loiseau N; Guillou H; Gamet-Payrastre L; Wahli W
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The latest idea in NAFLD/NASH pathogenesis.
    Ono M; Okamoto N; Saibara T
    Clin J Gastroenterol; 2010 Dec; 3(6):263-70. PubMed ID: 26190482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MAP4K4 signaling initiates metabolic reprogramming to protect hepatocytes from lipotoxic damage.
    Anand SK; Caputo M; Xia Y; Andersson E; Cansby E; Kumari S; Henricsson M; Porosk R; Keuenhof KS; Höög JL; Nair S; Marschall HU; Blüher M; Mahlapuu M
    J Lipid Res; 2022 Jul; 63(7):100238. PubMed ID: 35679904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
    Karim G; Bansal MB
    touchREV Endocrinol; 2023 May; 19(1):60-70. PubMed ID: 37313239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.